The use of testosterone after menopause

Journal of the British Menopause Society

Volumn 10, Issue 2, 2004, Pages 65-69

  Davis, Susan R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b Jean Hailes Foundation for Women's Health   (Australia)

Author keywords

Androgen; Libido; Menopause; Sexual receptivity; Testosterone

Indexed keywords

ESTROGEN; METHYLTESTOSTERONE; TESTOSTERONE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ACNE; ALOPECIA; ANDROGEN THERAPY; BREAST CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG PELLET; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIRSUTISM; HUMAN; LARYNX DISORDER; LIVER DYSFUNCTION; LONG TERM CARE; MENOPAUSAL SYNDROME; MENOPAUSE; PATIENT SATISFACTION; PREMENOPAUSE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; VAGINA DISEASE; VIRILIZATION;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGNOSIS; RISK ASSESSMENT; TESTOSTERONE; TREATMENT OUTCOME;

EID: 7744221806     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/136218004774202373     Document Type: Review

References (54)

1. Bachmann GA, Bancroft J, Braunstein G, et al. Female androgen insufficiency: The Princeton Consensus Statement on definition, classification and assessment. Fertil Steril 2002; 77: 665.
2. Judd HL, Yen SSC. Serum and androstenedione and testosterone levels during the menstrual cycle. J Clin Endocrinol Metab 1973; 36: 475-481.
3. Vierhapper H, Nowotny P, Waldhausl W. Determination of testosterone production rates in men and women using stable isotope dilution and mass spectromety. J Clin Endocrinol Metab 1997; 82: 1492-1496.
4. Rannevik G, Jeppsson S, Johnell O. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1986; 8: 189-196.
5. Davis SR. Androgen Replacement in Women: A Commentary. J Clin Endocrinol Metab 1999; 84: 1886-1891.
6. Judd HL, Judd G, Lucas WE, Yen SSC. Endocrine function of the postmenopausal ovary. Concentrations of androgens and estrogens in ovarian and peripheral venous blood. J Clin Endocrinol 1974; 39: 1020-1025.
7. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, Von Muhlen D. Hysterectomy,oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85: 645-651.
8. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-1430.
9. Burger HG, Dudley EC, Hopper DL. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995; 80: 3537-3545.
10. Labrie F, Belanger A, Cusan L, Gomez J-L, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated andrgoen metaboliltes during aging. J Clin Endocrinol Metab 1997; 82: 2396-2402.
11. Couzinet B, Meduri G, Lecce M, et al. The post menopausal ovary is not a major androgen producing gland. J Clin Endocrinol Metab 2001; 86: 5060-5065.
12. Judd HL, Lucas WE, Yen SSC. Effect of oopherectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1994; 118: 793-798.
13. Nathorst-Boos J, von Schoultz H. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992; 34: 97-101.
14. Janson P, Janson I. The acute effect of hysterectomy on ovarian blood flow. Am J Obstet Gynecol 1977; 127: 349-352.
15. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974; 39: 340-346.
16. Miller K, Sesmilo G, Schiller A, et al. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86: 561-567.
17. Doldi N, Belvisi L, Bassan M, Fusi F, Ferrari A. Premature ovarian failure:steroid synthesis and autoimmunity. Gynecol Endocrinol 1998; 12; 23-28.
18. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study. J Clin Endocrinol Metab 1998; 83: 2717-2725.
19. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25: 285-289.
20. Booij A, Biewenga-Booij CM, Huber-Bruning O, et al. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 811-886.
21. Mathur RS, Landgreve SC, Moody LO, et al. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in postmenopausal women. Maturitas 1985; 7: 129-133.
22. Vermeulen A, Verdonck L, Kaufman M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672.
23. Klee GG, Heser D. Techniques to measure testosterone in the elderly. Mayo Clinic Proceedings 2000; 75: S19-S25.
24. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982; 16: 801-810.
25. Montgomery J, Brincat M, Appleby L, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987; 1 (8528): 297-299.
26. Brincat M, Studd JWW, O'Dowd T, et al. Subcutaneous hormone implants for the control of climacteric symptoms. Lancet 1984; 1 (8367): 16-18.
27. Burger HG, Hailes J, Nelson J, Menelaus M. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. Br Med J 1987; 294: 936-937.
28. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985; 151: 153-160.
29. Shifren JL, Braunstein G, Simon J, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Eng J Med 2000; 343: 682-688.
30. Goldstat R, Briganti E, Tran J, Wolfe R, Davis S. Transdermal testosterone improves mood, well being and sexual function in premenopausal women. Menopause 2003; 10: 390-398.
31. Davis S, Rees M, Ribot J, et al. Efficacy and safety of testosterone patches for the treatment of low sexual desire in surgically menopausal women. 59th Annual Meeting of the American Society for Reproductive Medicine, San Antonio, Texas, 11-15th October 2003.
32. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in surgical menopause. Psychosom Med 1985; 47: 339-351.
33. Burger HG, Hailes J, Menelaus M. The management of persistent symptoms with estradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 1984; 6: 351-358.
34. Davis SR, McCloud PI, Strauss BJG, Burger HG. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227-236.
35. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. sexual behaviour and neuroendocrine response. J Reprod Med 1998; 43: 847-856.
36. Myers L, Dixen J, Morrissette D, et al. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1980; 70: 1124-1131.
37. Lobo R, Rosen RC, Yang H-M, et al. Comparative effects of oral esterified estrogens with and without methyl testosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341-1352.
38. Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002; 5: 357-365.
39. Colvard DS, Eriksen EF, Keeting PE. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989; 86: 854-857.
40. Kasperk CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576-1578.
41. Simberg N, Titinen A, Silfrast A, et al. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. J Clin Endocrinol Metab 1995; 81: 646-651.
42. Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass, and bone loss. A propspective study of pre-, peri- and postmenopausal women. J Clin Invest 1996; 97: 14-21.
43. Nilas L, Christiansen C. Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 1987; 65: 697-699.
44. Heiss CJ, Sanborn CF, Nichols DL. Associations of body fat distribution, circulating sex hormones and bone density in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1591-1596.
45. Watts NB, Notelovitz M, Timmons MC. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85: 529-537.
46. Raisz LG, Witta B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1995; 81: 37-43.
47. Savvas M, Studd JWW, Fogelman I, et al. Skeletal effects of oral estrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 1988; 297: 331-333.
48. Savvas M, Studd JWW, Norman S, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992; 99: 757-760.
49. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in post-menopausal women. Menopause 2000; 7: 395-401.
50. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993; 82:919-924.
51. Secreto G, Toniolo P, Berrino E, et al. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res 1991; 51: 2572-2576.
52. Berrino F, Muti P, Michelli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88: 291-296.
53. Zhou J, Ng S, Adesanya-Famuiya O, et al. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000; 14: 1725-1730.
54. Buckler HM, McElhone K, Durrington PN, et al. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) 1998; 49: 173-178.